What is the translation of " CROSSOVER STUDY " in Croatian?

• ukriženom ispitivanju
• križnom ispitivanju

Examples of using Crossover study in English and their translations into Croatian

The randomized, placebo-controlled, double-blind crossover study included 16 overweight adults and lasted 22 weeks.
Randomizirana, placebo kontrolirano, dvostruko slijepo, ukrižena studija uključeno 16 odraslih težine i trajalo je 22 tjedana.

The effect of idelalisib(150 mg and 400 mg) on the QT/QTc interval was evaluated in a placebo- and positive-controlled(moxifloxacin 400 mg) crossover study in 40 healthy subjects.
Učinak idelalisiba(150 mg i 400 mg) na QT/QTc interval ocijenjen je crossover ispitivanjem kontroliranim placebom i pozitivnom kontrolom(moksifloksacin 400 mg) u 40 zdravih ispitanika.

In a single dose, crossover study of desloratadine, the tablet and the syrup formulations were found to be bioequivalent.
U ispitivanju naizmjenične primjene jedne doze utvrđeno je da su formulacije desloratadina u obliku tableta i sirupa bioekvivalentne.

QTcF interval was evaluated in a randomised, placebo and active(moxifloxacin 400 mg once daily) controlled crossover study in 39 healthy adults, with 10 measurements over 12 hours on Day 3.
QTcF interval procijenjen je u randomiziranom, s placebom i aktivnom kontrolom(moksifloksacin 400 mg jednom dnevno) kontroliranoj crossover studiji u 39 zdravih osoba, s 10 mjerenja kroz 12 sati tijekom trećeg dana studije.

In a randomized crossover study on patellar tendinopathy, Dr. Hans Zwerver, a specialist in sports medicine from the University Medical Center Groningen, researched the effect of the GenuPoint support on the patellar tendon.
U randomiziranoj presječnoj studiji o patelarnoj tendopatiji, sportski liječnik Dr. Hans Zwerver iz Sveučilišnog medicinskog centra Groningen istražio je djelovanje bandaže GenuPoint na patelarnu tetivu.

QTcF interval was evaluated in a randomised, placebo and active(moxifloxacin 400 mg once daily) controlled crossover study in 45 healthy adults, with 10 measurements over 12 hours on Day 3.
U randomiziranom, placebom i aktivno(moksifloksacin 400 mg jedanput na dan) nadziranom, ukriženom ispitivanju u 45 zdravih odraslih osoba, s 10 mjerenja tijekom 12 sati trećeg dana ispitivanja evaluiran je QTcF interval.

In a double-blind, crossover study, the reduction in glycosylated haemoglobin levels after 12 weeks dosing was 0.37 percentage points with insulin lispro, compared to 0.03 percentage points for soluble insulin p 0.004.
U dvostruko slijepom ukriženom ispitivanju razine glikoziliranog hemoglobina smanjene su za 0, 37 postotnih bodova nakon 12 tjedana liječenja inzulinom lispro, a za 0, 03 postotna boda nakon primjene topljivog inzulina p 0, 004.

The effect of rilpivirine at the recommended dose of 25 mg once daily on the QTcF interval was evaluated in a randomised, placebo and active(moxifloxacin 400 mg once daily) controlled crossover study in 60 healthy adults, with 13 measurements over 24 hours at steady-state.
Učinak rilpivirina u preporučenoj dozi od 25 mg jedanput dnevno na QTcF interval procijenjen je u randomiziranom križnom ispitivanju kontroliranom placebom i djelatnom tvari(moksifloksacin 400 mg jedanput dnevno) u 60 zdravih odraslih ispitanika, uz 13 mjerenja tijekom 24 sata u stanju dinamičke ravnoteže.

Plasma bimatoprost and timolol concentrations were determined in a crossover study comparing the monotherapy treatments to GANFORT(multi-dose formulation) treatment in healthy subjects.
Koncentracije bimatoprosta i timolola u plazmi utvrđene su u studiji s križnom zamjenom skupina u kojoj su uspoređivana monoterapijska primjena s primjenom GANFORT-a(višedozni pripravak) u zdravih osoba.

In a crossover study in 27 HIV-infected patients, intracellular carbovir-TP exposures were higher for the abacavir 600 mg once daily regimen(AUC24,ss+ 32%, Cmax24,ss+ 99% and Ctrough+ 18%) compared to the 300 mg twice daily regimen.
U križnoj studiji 27 bolesnika zaraženih virusom HIV-a, unutarstanična izloženost karbovir-TP-u bila je veća pri doziranju od 600 mg abakavira jedanput na dan(AUC24, ss+ 32%, Cmax24, ss+ 99% and Ctrough+ 18%) u usporedbi s 300 mg dvaput na dan.

The pharmacokinetic evaluation was repeated for RIXUBIS in an open-label, uncontrolled study with RIXUBIS in male subjects who participated in the initial PK crossover study and had received prophylaxis with RIXUBIS for 26±1 weeks(mean± SD) and accumulated at least 30 exposure days(EDs) to RIXUBIS.
Farmakokinetička procjena ponovljena je za lijek RIXUBIS u otvorenom, nekontroliranom ispitivanju s lijekom RIXUBIS na muškim ispitanicima koji su sudjelovali u početnom farmakokinetičkom, ukriženom ispitivanju i koji su primili profilaksu s lijekom RIXUBIS tijekom 26±1 tjedna( srednja vrijednost ± SD) i prikupili barem 30 dana izloženosti lijeku RIXUBIS.

A double-blind, randomized, placebo-controlled crossover study found that a 200 mg dose of Modafinil was able to produce a similar pattern of cognitive enhancement in patients with ADHD compared to healthy patients.
Dvostruko slijepa, randomizirana, placebo-kontrolirana crossover studija pokazala je da je doza 200 mg Modafinila bila u stanju proizvesti sličan uzorak kognitivnog poboljšanja u bolesnika s ADHD-om u usporedbi sa zdravih pacijenata.

A crossover study in 40 healthy subjects, 10 each in the four CYP2C19 metaboliser groups(ultrarapid, extensive, intermediate and poor), evaluated pharmacokinetic and antiplatelet responses using 300 mg followed by 75 mg/day and 600 mg followed by 150 mg/day, each for a total of 5 days steady state.
U križnoj studiji na 40 zdravih ispitanika, po 10 iz svake od 4 skupine CYP2C19 metabolizatora(vrlo brzi, brzi, intermedijarni i spori), procijenjen je farmakokinetički i antitrombocitni odgovor upotrebom doze od 300 mg, nakon čega je slijedila doza od 75 mg/dan te doze od 600 mg, nakon čega je slijedila doza od 150 mg/dan, u trajanju od ukupno 5 dana stanje dinamičke ravnoteže.

Another randomised, double-blind, multiple- dose, comparator-controlled, two-way crossover study in 50 healthy volunteers showed that the pharmacokinetic profile of Nivestim was comparable to that of the reference product after subcutaneous administration.
Drugo randomizirano, dvostruko slijepo, dvosmjerno ukriženo ispitivanje višestrukih doza kontrolirano komparatorom koje je uključivalo 50 zdravih ispitanika pokazalo je da Nivestim ima farmakokinetički profil usporediv s profilom referentnog lijeka nakon supkutane primjene.

In a pharmacokinetic crossover study(AC-052-116), 16 healthy adult subjects received 62.5 mg bosentan using the 62.5 mg film-coated tablet formulation or 64 mg bosentan using the 32 mg dispersible tablet formulation.
U krosover ispitivanju farmakokinetike(AC-052-116), 16 zdravih odraslih ispitanika primilo je 62, 5 mg bosentana u obliku 62, 5 mg formulacije filmom obloženih tableta ili 64 mg bosentana u obliku 32 mg tablete za oralnu suspenziju.

This evaluation was conducted in a Phase 1, double-blind, randomized, crossover study to define the ECG effects of amifampridine phosphate at these doses compared to placebo and moxifloxacin(a positive control) in healthy men and women who are slow acetylators n=52.
Ova je procjena provedena u dvostruko slijepom, randomiziranom, ukriženom ispitivanju faze 1 za definiranje EKG učinka amifampridin fosfata u tim dozama u usporedbi s placebom i moksifloksacinom(pozitivna kontrola) u zdravih muškaraca i žena koji su spori acetilatori n=52.

In a crossover study in 60 healthy volunteers, intracellular lamivudine-TP pharmacokinetic parameters were similar(AUC24,ss and Cmax24,ss) or lower(Ctrough- 24%) for the lamivudine 300 mg once daily regimen compared to the lamivudine 150 mg twice daily regimen.
U križnom ispitivanju na 60 zdravih dobrovoljaca, unutarstanični farmakokinetski parametri lamivudina-TP bili su slični(AUC24, ss i Cmax24,ss) ili niži(Ctrough- 24%) kad je lamivudin primijenjen u dozi od 300 mg jedanput na dan u odnosu na doziranje 150 mg dvaput na dan.

Pharmacokinetics of iloprost were investigated in a randomised, crossover study with 27 patients, stable on Ventavis 10 microgram/ml inhaled with I-Neb, following inhalation of single doses of 2.5 or 5 microgram iloprost using the Breelib or the I-Neb AAD nebuliser.
Farmakokinetika iloprosta ispitivana je u randomiziranom križnom ispitivanju na 27 bolesnika stabilnih na lijeku Ventavis 10 mikrograma/ml inhaliranom s I-Neb atomizatorom, nakon inhalacije jednokratnih doza od 2, 5 ili 5 mikrograma iloprosta pomoću atomizatora Breelib ili I-Neb AAD.

In an open-label, non-randomized, fixed-sequence, 3-period, 3-treatment, crossover study to evaluate the effect of multiple doses of ketoconazole on the single dose PK of naloxegol, co-administration of ketoconazole and naloxegol resulted in a 12.9 fold(90% CI: 11.3-14.6) increase in naloxegol AUC and a 9.6-fold increase in naloxegol Cmax(90% CI: 8.1-11.3), compared to when naloxegol was administered alone.
U otvorenom, nerandomiziranom, ukriženom ispitivanju u 3 razdoblja, s primjenom 3 liječenja u fiksnom redoslijedu, u kojem se ocjenjivao učinak višekratnih doza ketokonazola na farmakokinetiku jedne doze naloksegola, istodobna primjena ketokonazola i naloksegola povećala je AUC naloksegola 12, 9 puta(90% CI: 11, 3-14,6), a Cmax naloksegola 9, 6 puta(90% CI: 8, 1-11,3) u usporedbi s primjenom samo naloksegola.

In single-dose crossover studies of Aerius 5 mg orodispersible tablets with Aerius 5 mg conventional tablets, the formulations were bioequivalent.
U ispitivanjima naizmjenične primjene jedne doze Aerius 5 mg raspadljivih tableta za usta i konvencionalnih Aerius 5 mg tableta, te su formulacije bile bioekvivalentne.

Randomised, single-blind, single dose, crossover studies in 196 healthy volunteers showed that the pharmacokinetic profile of Biograstim was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomizirano, jednostruko slijepo, s jednom dozom, ukriženo ispitivanje u 196 zdravih dragovoljaca pokazalo je da je farmakokinetički profil Biograstima i pri supkutanoj i pri intravenskoj primjeni bio usporediv s farmakokinetičkim profilom referentnog lijeka.

Randomised, double-blind, single and multiple dose, crossover studies in 204 healthy volunteers showed that the pharmacokinetic profile of Filgrastim HEXAL was comparable to that of the reference product after subcutaneous and intravenous administration.
Randomizirana, dvostruko slijepa ukrižena ispitivanja primjene jednokratne i višekratnih doza u 204 zdravih dobrovoljaca pokazala su da se farmakokinetički profil lijeka Filgrastim HEXAL može usporediti s profilom referentnog lijeka nakon supkutane i intravenske primjene.

In two 8-month open label crossover studies, type 2 diabetes patients who were either new to insulin therapy or already using one or two injections of insulin, received 4 months of treatment with Humalog Mix25(used twice daily with metformin) and insulin glargine(used once daily with metformin) in a randomised sequence.
U dva 8-mjesečna, otvorena, ukrižena ispitivanja bolesnici sa šećernom bolešću tipa 2 koji prethodno nisu primali inzulinsku terapiju ili su već primali jednu ili dvije injekcije inzulina su tijekom 4 mjeseca nasumičnim redoslijedom dobivali Humalog Mix25(dvaput na dan s metforminom) i inzulin glargin jedanput na dan s metforminom.

In a single-dose three-way crossover design study evaluating healthy subjects, the mean maximum reduction in diastolic blood pressure was significantly greater following avanafil administered in combination with alcohol than following avanafil alone(3.2 mmHg) or alcohol alone(5.0 mmHg) see section 4.4.
U ispitivanju jednokratne doze s trostrukim ukrižavanjem u kojemu su se procjenjivali zdravi ispitanici, srednja vrijednost maksimalnog smanjenja dijastoličkog krvnog tlaka bila je značajno veća nakon primjene avanafila u kombinaciji s alkoholom nego nakon primijene samo avanafila(3, 2 mmHg) ili samo alkohola(5, 0 mmHg) vidjeti dio 4.4.